New drug duo enters human testing for Tough-to-Treat prostate cancer
NCT ID NCT07244341
Summary
This early-stage trial is testing the safety and initial effectiveness of combining two drugs, valemetostat and darolutamide, for men with metastatic prostate cancer that has stopped responding to standard hormone treatments. The study will enroll about 60 participants to find the right dose and see if the combination can help control the cancer. The main goal is to check how safe the drug combination is and how well patients tolerate it.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer Institute Hospital of JFCR
RECRUITINGKōtoku, 135-8550, Japan
-
Carolina Urologic Research Center
RECRUITINGMyrtle Beach, South Carolina, 29572-4607, United States
-
Kobe City Med Cen Gen Hosp.
RECRUITINGKobe, 650-0047, Japan
-
NEXT Oncology
RECRUITINGSan Antonio, Texas, 78229-6028, United States
-
Toho University Sakura Medical Center
RECRUITINGSakura-shi, 285-8741, Japan
-
Virginia Cancer Specialists (NEXT Virginia)
RECRUITINGFairfax, Virginia, 22031-2171, United States
Conditions
Explore the condition pages connected to this study.